Oppenheimer Maintains Outperform on Voyager Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Voyager Therapeutics (NASDAQ:VYGR) and keeps the price target at $18.
May 15, 2024 | 3:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson maintains an Outperform rating on Voyager Therapeutics and keeps the price target at $18.
The reaffirmation of an Outperform rating and a stable price target of $18 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100